Abstract:
본 발명에 따른 당화헤모글로빈 측정용 바이오센서는 기준전극; 및 집전체 상에, 당화헤모글로빈에 특이적 결합가능한 부위를 포함하고 외부로부터 전압 및 전류의 공급없이 당화헤모글로빈 결합에 의해 산화환원 반응전위가 변하는 분자들이 정렬된 변이전극을 구비한 측정부; 전위차분석법(Potentiometry)에 의해 변이전극과 기준전극 사이의 전위차를 측정하기 위한, 전위차 측정회로 또는 전위차 적정장치; 및 선택적으로 상기 변이전극과 기준전극 사이의 전위차이값 또는 이를 시료내 당화헤모글로빈의 량 또는 농도로 환산시켜 표시하는 표시부를 구비한다. 본 발명에 따른 당화헤모글로빈 측정용 바이오센서는 시료내의 당화헤모글로빈의 농도를 빠르고 정확하게 측정할 수 있는 효과가 있으며, 당화헤모글로빈의 농도측정시 헤모글로빈과 당화헤모글로빈의 분리단계를 거치지 않고 동시에 두 물질의 농도를 측정하여 그 비율을 구할 수 있다.
Abstract:
The present invention provides an arsenite oxidase enzyme modified to prevent translocation by modification of a translocation signal sequence. A microorganism modified to express the heterologous arsenite oxidase enzyme is also provided by the invention, together with a device for detecting the presence of arsenite in a sample.
Abstract:
Verification of patient sample electrolyte results using a separate quantitative measurement of sample resistivity. Sample resistivity may be used to measure small differences in resistivity of one sample to the next, and in comparison to a standard solution, in order to verify the results of sample electrolyte measurements being measured at the same time by, for example, individual ion selective electrodes (ISE) in a clinical analyzer. Providing a separate or secondary quantitative means for verification of the measured results of sample electrolytes using sample resistivity solves the problem of electrolyte result variability in sample electrolyte measurements. The process may compare a measured sample resistivity to an expected resistivity value as a verification of the accuracy of individual electrolyte results. Suspect samples - e.g., where the electrolyte resistivity results do not fit the expected resistivity - may be flagged. This separate verification step provides added confidence in the measured electrolyte results and can identify when problems occur or interferences are present in real time.
Abstract:
Described herein are devices, systems, and methods for determining the composition of liquids, including the identity of one or more drugs in the liquid, the concentration of the drug, and the type of diluent using immittance spectroscopy. These devices, systems and methods are particularly useful for describing the identity and, in some variations, concentration of one or more components of a medical liquid such as intravenous fluid. In particular, described herein are devices, systems and methods that may operate in low ionic strength diluents. Also described are methods of recognizing complex immittance spectrograph patterns to determine the composition of a liquid by pattern recognition.
Abstract:
A detection cell for a chromatography system includes a cell body having an inlet, an outlet, and a counter electrode, a working electrode, a sample flow passageway extending between the inlet and the outlet and in fluid contact with the counter and working electrodes, and a palladium/noble metal reference electrode system. A method of using the detection cell is also described.
Abstract:
This disclosure relates to sulfur sensors that utilize sensing materials that can be used to detect ultra low concentrations of sulfur in liquids, such as below even 15 ppm. The sulfur sensors comprise a sensing electrode having a material that contributes an electrical element to the analysis and a material that contributes an ionic element to the analysis.
Abstract:
Devices for detecting an analyte comprising a redox active analyte sensitive material on a working electrode and computer assisted signal acquisition and processing.
Abstract:
A test sensor includes a body, a first conductive trace, a second conductive trace, and a third conductive trace. The body includes a first region that has a fluid-receiving area, a second region separate from the first region, and a first temperature sensing interface disposed at or adjacent to the fluid-receiving area. The fluid-receiving area receives a sample. The first trace is disposed on the body, and at least a portion of the first trace is disposed in the first region. The second and third traces are disposed on the body. The third trace extends from the first to the second regions. The third trace is connected to the first trace at the first temperature sensing interface. The third trace includes a different material than the first trace. A first thermocouple is formed at the first temperature sensing interface. The thermocouple provides temperature data to determine an analyte concentration.
Abstract:
A thin film sensor, such as a glucose sensor, is provided for transcutaneous placement at a selected site within the body of a patient. The sensor includes several sensor layers that include conductive layers and includes a proximal segment defining conductive contacts adapted for electrical connection to a suitable monitor, and a distal segment with sensor electrodes for transcutaneous placement. The sensor electrode layers are disposed generally above each other, for example with the reference electrode above the working electrode and the working electrode above the counter electrode. The electrode layers are separated by dielectric layer.
Abstract:
A method is provided for determining analyte concentrations, for example glucose concentrations, that utilizes a dynamic determination of the appropriate time for making a glucose measurement, for example when a current versus time curve substantially conforms to a Cottrell decay, or when the current is established in a plateau region. Dynamic determination of the current peak-time to take the measurement allows each strip to operate in the shortest appropriate time frame, thereby avoiding using an average measurement time that may be longer than necessary for some strips and too short for others.